Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders.

p-in-epmc yes pmc-license-ref CC BY issue-copyright-statement © The Author(s) 2018 Introduction In around 50% of patients with myelodysplastic syndromes (MDS), clonal cytogenetic abnormalities are detectable by conventional chromosome banding (CCB) from bone marrow metaphases 1 – 3 The karyotype is highly significant for prognostication 2 – 6 and therapy allocation in patients with MDS and plays a fundamental role for the International Prognostic Scoring System (IPSS) 4 , its revised form, the IPSS-R 6 , 7 and the WHO adapted Prognostic Scoring System 8 , 9 .

also in 132,142 other papers